How reactive oxygen species (ROS) contribute to NLRP3 inflammasome activity has been debated. Findings now show that cofilin-1 binds and inhibits NLRP3 activation — an interaction that ROS can disrupt to enable inflammasome assembly.
Access to this article via Institution of Civil Engineers Library is not available. Burger, D., Fickentscher, C., De Moerloose, P.
& Brandt, K. J.
Sci. Rep.
6 , 29834 (2016). Institute for Molecular Bioscience, University of Queensland, St Lucia, Queensland, Australia K.S.
declares that they are a co-inventor on patents WO2018215818A1 WO2017140778A1 and WO2016131098A1 for NLRP3 inhibitors that have been licensed to Inflazome. Inflazome was acquired by Roche.
K.S. has served on the scientific advisory boards of Inflazome, Quench Bio and Novartis.
M.M. declares no competing interests.
Mellacheruvu, M., Schroder, K. ROS breaks the cofilin lock on NLRP3.
Nat Immunol (2026). https://doi.org/10.1038/s41590-026-02490-x
Nature Immunology published a clinical update in Infectious Disease on 21 Apr 2026.
The item focuses on ROS breaks the cofilin lock on NLRP3.
Review the original article for the full source wording and details.